Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
Takeaways Vertex’s suzetrigine filing is important because it could bring Canada its first new acute pain drug class in more than 20 years, which would give hospitals and payers a non-...
Biosimilars were introduced with the promise of expanding access to biologic therapies while reducing healthcare costs. As more blockbuster biologics lose exclusivity, biosimilars are becoming an incr...
The pharmaceutical industry is once again approaching a major patent cliff, with several blockbuster therapies set to lose exclusivity over the next few years. For many companies, these products have ...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
For decades, the pharmaceutical industry was built around the blockbuster model, developing medicines with broad indications capable of generating billions in annual revenue. These therapies, often de...
Takeaways Bepirovirsen’s Canada filing signals a coming shift in the hepatitis B market from lifelong viral suppression to time‑limited “functional cure” regimens, which could reshape how p...
Takeaways: Dr. Reddy’s has become the first company to secure Health Canada approval for a generic semaglutide injection (Ozempic equivalent), with an NOC covering 2 mg and 4 mg once‑weekly pens...
Takeaways: Bosaya and Vevzuo, layered on top of other recent denosumab biosimilar launches, should accelerate formulary switches and tender competition, strengthen Biocon’s credi...
